# Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation

> **NCT04234360** · PHASE3 · UNKNOWN · sponsor: **University Hospital, Montpellier** · enrollment: 600 (estimated)

## Conditions studied

- COPD Exacerbation

## Interventions

- **DRUG:** 5 days of systemic corticotherapy (prednisone)
- **DRUG:** 5 days of placebo

## Key facts

- **NCT ID:** NCT04234360
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-12
- **Primary completion:** 2024-10-12
- **Final completion:** 2025-01-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04234360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04234360, "Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04234360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*